Trading of Beximco Pharmaceuticals Limited’s Global Depository Receipts (GDRs) on the Alternative Investment Market (AIM) of the London Stock Exchange is set to be suspended due to the company’s failure to publish its annual financial report within the stipulated timeframe. According to the company, the suspension will take effect from 2 January 2026.

A GDR is a financial instrument that represents shares of a foreign company, allowing international investors to invest in it. In the case of Beximco Pharma, trading of these GDRs in the London market will be halted.

In a disclosure published on 19 December, the company stated that it would not be possible to publish the annual report and final financial results for the financial year ended 30 June 2025 by 31 December 2025, as required under AIM Rule 19. Beximco Pharma explained that the main reason for this delay is an ongoing case in the High Court challenging a decision of the Bangladesh Securities and Exchange Commission (BSEC) regarding the appointment of nine additional independent directors to the company’s board.

Following the fall of the Sheikh Hasina government in August 2025, the BSEC initiated the appointment of nine independent directors to Beximco Pharma’s board. The company filed a writ petition against this decision, and the matter is now sub judice. Due to the court’s vacation and bench reconstitution, the case will need to be heard afresh, and no verdict is expected before January 2026. As a result, board meetings to approve the accounts cannot be held, delaying the publication of the financial statements.

However, Beximco Pharma has clarified that the suspension of GDR trading in London will not affect its shares in the domestic market. Trading of Beximco shares on the Dhaka Stock Exchange (DSE) and Chittagong Stock Exchange (CSE) will continue as usual. The company also assured that all required disclosures will be made regularly in accordance with AIM rules during the suspension period.

According to financial indicators, Beximco Pharma’s earnings per share (EPS) for the first two quarters of the 2024–25 fiscal year stood at BDT 7.87. The company has also declared a 40 percent cash dividend for the financial year ended 30 June 2024.

On 24 December, each GDR last traded in the London market at £42.50. Beximco Pharma’s GDRs have been listed on the London Stock Exchange since September 2006.